open access
Gabapentin and tramadol for the treatment of postherpetic neuralgia. Preliminary study
open access
Abstract
Material and methods. Fourteen patients with PHN aged 54.1 years (SD = 7.6) were included into the study. The mean time from regression of skin lesions was 25.8 months (SD = 16.0). All patients suffered form neurophatic pain located in 2–5 thorax dermatoms (average 3.4, SD = 0.7), the mean pain intensity was 7 points in Visual Analogue Scale (VAS). All patients were previously treated with carbamazepine. After 2 weeks of wash-out period, treatment with tramadol (200 mg/d) and gabapentine (100 mg/d) was initiated. Dosage of gabapentine was increased by 100 mg every day until effective dose was reached. The effectiveness of treatment was determined by assessment of VAS in 2, 3, 4 and 5 week of treatment.
Results. Daily effective dose of gabapentine was 900–2400 mg, mean 1475 mg (SD = 413). The mean intensity of pain during last examination was 2.58 in VAS (SD = 51) and the difference form the initial evaluation of pain intensity was - 4.42 points (SD = 0,9) and was statistically significant (p < 0.05). The dosage of gabapetnine correlated with the number of affected skin dermatomes (χ2 = 32.0, p < 0.001). The treated group was small so the unexpectedly good results should undergo further investigation.
Conclusion. The use of gabapentine with tramadol in treatment of PHN gave good results. The effective dose of gabapentine may depend on the number of skin dermatoms affected with neuropatic pain.
Abstract
Material and methods. Fourteen patients with PHN aged 54.1 years (SD = 7.6) were included into the study. The mean time from regression of skin lesions was 25.8 months (SD = 16.0). All patients suffered form neurophatic pain located in 2–5 thorax dermatoms (average 3.4, SD = 0.7), the mean pain intensity was 7 points in Visual Analogue Scale (VAS). All patients were previously treated with carbamazepine. After 2 weeks of wash-out period, treatment with tramadol (200 mg/d) and gabapentine (100 mg/d) was initiated. Dosage of gabapentine was increased by 100 mg every day until effective dose was reached. The effectiveness of treatment was determined by assessment of VAS in 2, 3, 4 and 5 week of treatment.
Results. Daily effective dose of gabapentine was 900–2400 mg, mean 1475 mg (SD = 413). The mean intensity of pain during last examination was 2.58 in VAS (SD = 51) and the difference form the initial evaluation of pain intensity was - 4.42 points (SD = 0,9) and was statistically significant (p < 0.05). The dosage of gabapetnine correlated with the number of affected skin dermatomes (χ2 = 32.0, p < 0.001). The treated group was small so the unexpectedly good results should undergo further investigation.
Conclusion. The use of gabapentine with tramadol in treatment of PHN gave good results. The effective dose of gabapentine may depend on the number of skin dermatoms affected with neuropatic pain.
Keywords
neuropatic pain; postherapeutic neuralgia; gabapentine


Title
Gabapentin and tramadol for the treatment of postherpetic neuralgia. Preliminary study
Journal
Advances in Palliative Medicine
Issue
Vol 3, No 1 (2004): Polish Palliative Medicine
Pages
21-26
Published online
2003-10-27
Page views
1862
Article views/downloads
7999
Bibliographic record
Advances in Palliative Medicine 2004;3(1):21-26.
Keywords
neuropatic pain
postherapeutic neuralgia
gabapentine
Authors
Krzysztof Brzeziński
Wojciech Sodolski
Andrzej Horoch